BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bordeaux Neurocampus - ECPv4.9.10//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bordeaux Neurocampus
X-ORIGINAL-URL:https://www.bordeaux-neurocampus.fr/en/
X-WR-CALDESC:Events for Bordeaux Neurocampus
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240531T113000
DTEND;TZID=Europe/Paris:20240531T113000
DTSTAMP:20260405T072911
CREATED:20231010T125806Z
LAST-MODIFIED:20240524T144135Z
UID:163237-1717155000-1717155000@www.bordeaux-neurocampus.fr
SUMMARY:Friday Seminar - Günter Höglinger
DESCRIPTION:Venue: Centre Broca\n \n\nGünter Höglinger\nMunich Center for Neurosciences\nLudwig-Maximilians Universität Muchen\nhttps://www.mcn.uni-muenchen.de/members/regular/hoeglinger/index.html \nInvited by Wassilios Meissner (IMN) \nTitle\nSynNeurGe: Research criteria for a biological classification of Parkinson’s Disease \nAbstract\nWith the hope that disease-modifying treatments could target the molecular basis of Parkinson’s disease\, even before the onset of symptoms\, we propose a biologically based classification. Our classification acknowledges the complexity and heterogeneity of the disease by use of a three-component system (SynNeurGe): presence or absence of pathological α-synuclein (S) in tissues or CSF; evidence of underlying neurodegeneration (N) defined by neuroimaging procedures; and documentation of pathogenic gene variants (G) that cause or strongly predispose to Parkinson’s disease. These three components are linked to a clinical component (C)\, defined either by a single high-specificity clinical feature or by multiple lower-specificity clinical features. The use of a biological classification will enable advances in both basic and clinical research\, and move the field closer to the precision medicine required to develop disease-modifying therapies. We emphasise the initial application of these criteria exclusively for research. We acknowledge its ethical implications\, its limitations\, and the need for prospective validation in future studies. \n
URL:https://www.bordeaux-neurocampus.fr/en/event/friday-seminar-guenter-hoeglinger/
CATEGORIES:For scientists,home-event,Seminars
END:VEVENT
END:VCALENDAR